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Despite the global public health importance of resistance of micro-
organisms to the effects of antibiotics, and the direct relationship of
consumption to resistance, little information is available concerning
levels of consumption in Canadian hospitals and out-patient settings.
The present paper provides practical advice on the use of administra-
tive pharmacy data to address this need. Focus is made on the use of
the Anatomical Therapeutic Chemical classification and Defined
Daily Dose system. Examples of consumption data from Canadian
community and hospital settings, with comparisons to international
data, are used to incite interest and to propose uses of this informa-
tion. It is hoped that all persons responsible for policy decisions
regarding licensing, reimbursement, prescribing guidelines, formulary
controls or any other structure pertaining to antimicrobial use
become conversant with the concepts of population antibiotic con-
sumption and that this paper provides them with the impetus and
direction to begin accurately measuring and comparing antibiotic use
in their jurisdictions.
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Mesure de la consommation d’antibiotiques :
guide pratique concernant l’utilisation du
Système de classification anatomique thérapeu-
tique chimique et du système de posologie quoti-
dienne recommandée au Canada
Malgré l’importance, en santé publique, de la résistance des micro-
organismes aux effets des antibiotiques et le lien direct entre la
consommation et cette résistance, il existe peu de données sur le degré de
consommation des antibiotiques dans les hôpitaux et les services de
consultations externes au Canada. Le présent article donne des conseils
pratiques sur l’utilisation de données administratives en pharmacie à cet
égard. Il sera question en particulier du Système de classification
anatomique thérapeutique chimique et du système de posologie
quotidienne recommandée (« DDD »). Nous y présentons des exemples de
données sur la consommation de médicaments en milieu hospitalier et dans
la communauté au Canada par rapport à des données internationales pour
susciter l’intérêt et proposer des utilisations possibles de l’information
existante. Aussi espérons-nous que toutes les personnes responsables de
prises de décision en matière de politique concernant l’autorisation de mise
sur le marché, le remboursement, les lignes directrices sur les pratiques de
prescription, le contrôle des médicaments inscrits au formulaire ou toute
autre structure relative à l’utilisation des antimicrobiens connaissent les
concepts de consommation d’antibiotiques dans la population. Nous
espérons également que cet article leur donnera l’élan pour commencer à
mesurer précisément et à comparer l’utilisation des antibiotiques sur leur
territoire et les orientera dans leur démarche.
WHY MEASURE ANTIBIOTIC CONSUMPTION?
Antibiotic resistance is a global public health problem. While
many reports have described serious misuse of antibiotics and
the need for rational antibiotic prescribing practices (1-5),
there are surprisingly few published descriptions or compar-
isons of antibiotic consumption (6-12). This lack of informa-
tion has hindered rational discussions about desirable levels of
consumption – the ultimate objective of all concerned with
this issue. Many factors must be considered in attempting to
define best levels of consumption, including local disease
prevalence, susceptibility patterns, antibiotic prescribing prac-
tices and philosophy of their use. Comparisons with other 
populations, especially similar ones, help to give context. A
reasonable question posed by an Argentinean researcher
attempting to define the “right” amount of antibiotic con-
sumption for Argentina might be, ‘Is the level of antibiotic
consumption better in Argentina than in Canada?’ Of course,
the starting point for this exercise is to state what the respec-
tive levels of consumption are in units that are understandable
in both Argentina and Canada. This is not possible at present.
Until such time as fundamental measurements of consumption
are routinely available to researchers, advisors, clinicians and
policy-makers, it will continue to be difficult to address this
growing problem.
HOW TO GET STARTED
The present paper focuses on practical advice on the utiliza-
tion of administrative data in the community and hospitals for
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expression of antibiotic consumption in internationally
accepted formats. Of course, the ability to start the process is
dependant upon access to administrative data. Fortunately,
because in many jurisdictions pharmaceuticals are paid for or
administered by government agencies, accurate data concerning
expenditures are kept. The focus is often financial but volume
data are associated.
While any level of aggregated administrative data can be uti-
lized, systems vary widely in the type of information collected.
The most desirable level is the simplest one (eg, number of
tablets dispensed to an individual on a single prescription).
However, aggregated data at a higher level can also be useful
(eg, number of grams dispensed in a country in a year).
DRUG CLASSIFICATION SYSTEMS
Identifying individual drugs
Countries and hospitals vary widely in the classification systems
used for pharmaceuticals. In Canada a Drug Identification
Number (DIN) is assigned by the Therapeutic Products
Directorate – the national agency that licenses prescription
drugs. This number uniquely identifies the active ingredient,
manufacturer, trade name, strength, route of administration
and dosage form. This type of classification number is often
used in government pharmaceutical claims and can be com-
bined with another classification system to facilitate standard-
ized expressions of utilization data.
Classification of drugs by therapeutic categories
The most widely used, and most useful, classification system for
the expression of drug utilization is the Anatomical Therapeutic
Chemical (ATC) classification system. The rest of the present
paper focuses on the use of this system.
The ATC classification
The ATC system was initiated in the 1970s by the Norwegian
Medicinal Depot, and is now coordinated by the World Health
Organization (WHO) Collaborating Centre for Drug Statistics
Methodology, established in Oslo in 1982. The centre revises
the ATC codes as necessary and maintains an online database
and published index. Drugs are divided into different groups
according to the organ or system on which they act and/or their
therapeutic and chemical characteristics. Each drug is assigned
at least one ATC code, which are classified into groups at five
different levels. See Table 1 for an illustration using amoxicillin.
Defined daily dose
To facilitate the ability to compare consumption information
across time and geography, a technical unit of measurement was
created for use in conjunction with the ATC classification. It is
referred to as the Defined Daily Dose (DDD) and assigned to each
drug at the 5th level (chemical substance) classification. It is
defined by the ATC as the assumed average maintenance dose per
day for a drug used for its main indication in adults and is assigned
by the WHO Collaborating Centre using established principles
(see Resources section of this paper). Different DDDs may be
assigned for different drug formulations (ie, parenteral versus oral).
See Table 2 for some examples of DDDs for antibiotics.
How does one use the ATC/DDD classification with
administrative prescription claims data?
If data are available at an individual claim level and the drug is
identified with a unique DIN, it is a fairly straightforward
process to apply the ATC classification and convert drug quan-
tity into a number of DDDs.
Consider the following hypothetical example (Figure 1) of
the application of ATC/DDD to a single prescription claim
from a 59-year-old woman with unique Identification Number
545561 dispensed 14 ciprofloxacin 500 mg tablets from a phar-
macy in Greenville in September 1995. In this example
ciprofloxacin 500 mg tablets are identified with a unique DIN
of 1663.
The number of DDDs is a calculated field obtained by mul-
tiplying the quantity field by the DDD conversion factor field.
In this example, the strength of one tablet is 500 mg and the
ATC/DDD is 1 g for ciprofloxacin. Each 500 mg tablet is
equivalent to 0.5 DDD. Multiplication of the quantity dis-
pensed (14 tablets) by a conversion factor of 0.5 equals a total
of 7 DDDs dispensed from this prescription.
Data can then be collated, expressed and evaluated based
on any other field in the merged record.
Use of ATC/DDD with hospital pharmacy data
Most hospital pharmacies have the ability to express their
drug dispensing information in monthly collations of num-
bers of drugs dispensed by type of drug. If the ATC system is
in use in the hospital the information will be routinely
expressed in ATC language. If not, as is usual in Canada, the
ATC/DDD system can be applied in a similar fashion to the
above out-patient prescription example. Commonly, a unique
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TABLE 1
Classification of amoxicillin of the Anatomical Therapeutic Chemical (ATC) classification system
ATC classification ATC category Description
J General anti-infectives for systemic use 1st level, anatomical main group
J01 Antibacterials for systemic use 2nd level, therapeutic main group
J01C Beta-lactam antibacterials, penicillins 3rd level, therapeutic/pharmacological subgroup
J01C A Penicillins with extended spectrum 4th level, chemical/therapeutic/pharmacological subgroup
J01C A04 Amoxicillin 5th level, subgroup for chemical substance
TABLE 2
Examples of Defined Daily Doses
ATC classification ATC drugs Defined Daily Dose
J01C A04 Amoxicillin 1 g (oral or parenteral)
J01M A06 Norfloxacin 0.8 g (oral)
J01M A02 Ciprofloxacin 1 g (oral)
0.5 g (parenteral)
J01F F01 Clindamycin 1.2 g (oral)
1.8 g (parenteral)
J01C A12 Piperacillin 14 g (parenteral)
ATC Anatomical Therapeutic Chemical 
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DIN or alphanumeric mnemonic is assigned by the hospital or
the manufacturer of the pharmacy operating system that iden-
tifies drug, strength and form. The creation of an association
file that links the DIN or mnemonic with the ATC/DDD code
allows the merging of hospital pharmacy information with
ATC/DDD classification.
Consider this example of a report of antibiotics dispensed to
hypothetical surgical ward 4West in the month of January
2003 (Figure 2). In this case, the drug description field identi-
fies the drug, the strength and the form.
The number of DDDs is calculated by multiplying the units
dispensed field with the DDD conversion factor field. In this case,
300 Cefazolin 1 g vials are converted to 100 DDDs. Now the
information can be expressed in DDDs by the ATC classification.
Expressing consumption information
Because the ATC/DDD system is continuously being modified,
it is essential that the version (year) of ATC classification in
use is clearly identified. By convention, the most recent classi-
fication is usually used. However, one must be aware of
changes in the classification or DDD assignment when com-
paring with historic information (13,14). All expressions of
consumption information in this paper utilize the 2002 version
of the ATC/DDD classification.
Rates
Most commonly, drug consumption is expressed as a rate. Of
course, to express a rate, a denominator and time unit must
be defined. Common units for antibiotic consumption
include DDD per 1000 inhabitant-days for out-patient data
and DDD per 100 bed-days in hospitals.
For expressions of antibiotic consumption at the level of a
country, province or large region, census population estimates
are appropriate. Statistics Canada is a readily available source.
Consider the following example from British Columbia (BC).
BC PharmaNet is a government program administered through
the BC College of Pharmacists that receives and collates infor-
mation from all pharmacies in the province. They provided
information to the BC Centre for Diseases Control, who
applied ATC/DDD in a fashion analogous to the example given
in the section on claims information.
Calculation of yearly rates
Here is an example showing the calculation of yearly rates:
Total amount of antibiotics in J01 category dispensed in 1996:
26,916,839 DDD
Population (from Census): 3,959,698
26916839 DDD = 6.80 DDD/inhabitant-year
3,959,698
6.80 × 1000 = 18.63 DDD/1000 inhabitant-days 
365
The data (ATC 2000) from British Columbia from 1997 to
2000 is graphically represented in Figure 3.
Consumption levels were quite stable at a rate of approxi-
mately 18 DDD per 1000 inhabitant-days during these four
Measurement of antibiotic consumption: ATC/DDD methodology
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Figure 1) Process of merging typical outpatient pharmacy dispensing data with Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD)
DIN PatientID Number Drug Name Form Strength Quantity Location Sex Age Month
1663 545561 ciprofloxacin Tablet 500mg 14 Greenville F 59 09/95
+
An ATC/DDD association file is created that associates the ATC classification with the Drug 
Identification Number (DIN). 
ATC/DDD Classification Association File 
DIN ATCLevel 1 
ATC
Level 2 
ATC
Level 3 
ATC
Level 4
ATC
Level 5
ATC
DDD
DDD Conversion
Factor 
1663 J 01 M A 02 1.0 0.5 
↓
This is then merged with the claim information linked by DIN. 
Merged Record 
DIN PatientID Number Drug Name Form Strength Quantity Location Sex Age Month
1663 545561 ciprofloxacin Tablet 500mg 14 Greenville F 59 09/95
DIN ATCLevel 1 
ATC
Level 2 
ATC
Level 3 
ATC
Level 4
ATC
Level 5
ATC
DDD
DDD Conversion 
Factor DDDs 
1663 J 01 M A 02 1.0 0.5 7
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years. Comparing these rates with those of Denmark, published
in the 2002 Danish Integrated Antimicrobial Resistance
Monitoring and Research Programme report (15), gives some
context (Figure 4).
The consumption in Denmark was also stable, but at a much
lower level, approximately 12 DDD per 1000 inhabitant-days. In
ambulatory care, the people of BC consumed about 50% more
antibiotics than did the people of Denmark.
Hutchinson et al
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Figure 4) J01 Antibiotic consumption in ambulatory care patients in British
Columbia (BC) and Denmark, 1997 to 2000. DDD Defined Daily Dose
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Figure 3) J01 Antibiotic consumption in ambulatory care patients in
British Columbia, 1997 to 2000. DDD Defined Daily Dose
Monthly Report of Antibiotic Use  
Ward 4West Surgery January 2003 
Mnemonic 
(Identifier)
Drug Description Units Dispensed 
CEFA1I Cefazolin 1 gram vial 300 
CEFU750I Cefuroxime 750 mg vial 128 
CIPRO500T Ciprofloxacin 500 mg tablet 96 
+
A file associating mnemonic (identifier) to ATC / DDD is created: 
Mnemonic ATCLevel 1 
ATC
Level 2 
ATC
Level 3
ATC
Level 4
ATC
Level 5
ATC
DDD
DDD Conversion 
Factor 
CEFA1I J 01 D A 04 3.0 0.333 
CEFU750I J 01 D A 06 3.0 0.25 
CIPRO500T J 01 M A 02 1.0 0.5 
↓
This is then merged with the monthly report linked by Mnemonic. 
Mnemonic 
(Identifier)
Drug Description Units Dispensed 
CEFA1I Cefazolin 1 gram vial 300 
CEFU750I Cefuroxime 750 mg vial 128 
CIPRO500T Ciprofloxacin 500 mg tablet 96 
Mnemonic ATCLevel 1 
ATC
Level 2 
ATC
Level 3
ATC
Level 4
ATC
Level 5
ATC
DDD
DDD Conversion 
Factor DDDs 
CEFA1I J 01 D A 04 3.0 0.333 100
CEFU750I J 01 D A 06 3.0 0.25 32
CIPRO500T J 01 M A 02 1.0 0.5 48
Figure 2) Process of merging typical monthly hospital pharmacy data with Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD)
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A closer look at a specific class of antibiotic reveals further
differences. A comparison of rates of consumption of Class
J01MA – Fluoroquinolones in BC and Denmark, expressed
monthly from 1997 to 2000 is shown in Figure 5. These Danish
data were obtained from the Danish Medicines Agency by one
of the authors (DM).
Fluoroquinolones were consumed at a much higher rate in
British Columbia than in Denmark during this time period and
the rate increased in British Columbia while it decreased in
Denmark. These differences are easier to see if two different
Y-axis scales are employed (Figure 6).
The reduction in consumption in Denmark immediately
followed removal of subsidization for fluoroquinolones by the
Danish drug plan (16).
Expressing consumption in hospitals
The usual divisions within a hospital are wards (physical divi-
sions) or services (patient group divisions). If information is
available divided by service (eg, General Surgery Service,
Orthopedic Service), it is preferable to physical ward divisions,
which often care for patients from several services (‘off-service’
patients). The usual volume denominator for hospital statistics
is patient-day (often referred to as bed-day). By convention,
the discharge day for each patient is not counted to avoid the
inflation of the denominator by partial days (admission day
and discharge day) being counted as full days.
Consider this example of consumption of category J01
(Antibacterials for systemic use) on the General Surgery
Service in the Health Sciences Centre in St John’s,
Newfoundland from January 1999 to August 2003 in monthly
measurements (Figure 7).
The average use was approximately 80 DDD per 100 bed-days
in the first two years with considerable month-to-month
variation. A 12-month moving average helps to smooth varia-
tion and display an upward increase in the last year of the eval-
uation period to approximately 90 DDD per 100 bed-days.
Comparisons between similar services in different institu-
tions may yield useful information. Consider this comparison
of consumption of ciprofloxacin in the Urology Service of the
Healthcare Corporation of St John’s with the Urology Service
of the Calgary Health Region from April 1999 to October
2002 in monthly data points (Figure 8). 
The consumption rate of ciprofloxacin was much higher in
St John’s than in Calgary during this period; the rate of
increase was also greater in St John’s. An even closer look
demonstrates that the differences were even more pronounced
when the intravenous (IV) form of ciprofloxacin is examined
in isolation (Figure 9).
There were very large month-to-month variations in St John’s,
with large increases in the past 18 months. This was not the
case in Calgary.
Uses for antibiotic consumption information
Routine measurement and display of consumption information
to prescribers and policy-makers are a first step in increasing the
awareness and importance of careful antibiotic use. It is then
possible to attempt to define levels of optimal use.
Measurement of antibiotic consumption: ATC/DDD methodology
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Figure 5) Comparison of rates of consumption of Class J01MA –
Fluoroquinolones in British Columbia (BC) and Denmark expressed
monthly from 1997 to 2000. DDD Defined Daily Dose
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Figure 6) Comparison of rates of consumption of class J01MA fluoro-
quinolones in British Columbia (BC) and Denmark with different 
Y-axes. BC is on the left, Denmark is on the right. DDD Defined Daily
Dose
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Figure 7) J01 antibiotic use in the Health Sciences Centre’s surgery
service from January 1999 to August 2003 in monthly measurements.
DDD Defined Daily Dose; Mov Avg Moving average
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Comparative information can help to define those levels by
evaluating individual consumption and proportions in the
context of recognized leaders in the area. Conformity to local
practice guidelines can be evaluated, and expected levels of
consumption can be estimated by defining the incidence of
disease requiring antimicrobial therapy. Feedback to pre-
scribers is one potential form of intervention.
Provincial pharmacare plans
Consider the circumstance of pharmacy plan policy-makers in
the province of BC. Examples of important and reasonable
questions generated by analysis of consumption data are:
1. Is the overall level of consumption of antibiotics better in
Denmark or in BC?
a. What measures of health might help to answer this
question?
b. What are the effects on antibiotic resistance?
2. Is the level of antibiotic consumption in BC justifiable by
rates of bacterial infections?
3. Is it desirable to have increasing rates of consumption of
fluoroquinolones?
a. What are the health advantages?
i. In the short term?
ii. In the long term?
b. What are the costs?
i. In the short term?
ii. In the long term?
4. What policy tools are available to influence consumption?
These types of questions could and should be posed by all
pharmacy plan decision-makers when evaluating plan policies
as they pertain to existing antibiotics but, in particular, to new
antibiotics. Potential changes to population antibiotic con-
sumption should be a consideration in all formulary decisions.
Hospitals
In the case of use of the Surgery Service in St John’s, a rational
question might be, “What explains the increase in antibiotic
consumption in the past year?” The ability to ask this complex
question serves to focus attention on the issue at the level of
service administrators and prescribers. While there are many
potential explanations, engaging the decision-makers in the
process is essential if attention is to be focused on optimizing
antibiotic use.
The specific example of the use of ciprofloxacin, in particular
IV ciprofloxacin on the Urology Service in St John’s in com-
parison wtih Calgary, prompts other questions:
1. Are the patients comparable on these Services?
a. How can they be characterized?
i. Age/Sex
ii. Procedures
iii. Diagnoses
iv. Length of Stay
2. Are the rates of infection different on these two Services?
3. Are the bacterial pathogens different?
a. Identity
b. Susceptibility
4. What explains the increase in the IV form of ciprofloxacin
use, particularly in St John’s?
a. New medical information?
b. Guidelines?
c. Change in patient population (eg, higher proportion
unable to eat?)
By answering these questions, it will be possible to define
means of comparing these two services that are understandable
and meaningful to both. It is possible that this will engender dis-
course that will help to define optimal antibiotic use in both
Urology services.
Hutchinson et al
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Figure 9) Comparison of consumption of the intravenous (IV) form of
ciprofloxacin (J01MA02) in the Urology Service of the Healthcare
Corporation of St John’s with the Urology Service of the Calgary
Health Region from April 1999 to October 2002 in monthly data
points. DDD Defined Daily Dose
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Figure 8) Comparison of consumption of ciprofloxacin (J01MA02) in
the Urology Service of the Healthcare Corporation of St John’s with the
Urology Service of the Calgary Health Region from April 1999 to
October 2002 in monthly data points. DDD Defined Daily Dose
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SUMMARY
It is our hope that this document stimulates further interest in
measurement and display of population antibiotic consump-
tion. All persons responsible for policy decisions regarding
licensing, reimbursement, prescribing guidelines, formulary
controls or any other structure pertaining to antimicrobial use
should be conversant with the concepts of population antibi-
otic consumption. Prescribers should be made aware of their
own prescribing practices in the context of recognized leaders.
The sooner we are able to accurately measure and compare our
antibiotic prescribing and consuming behaviour, the sooner we
will be able to have reasoned, practical approaches to improve-
ment.
RESOURCES
The WHO Collaborating Centre for Drug Statistics Methodology
has an excellent website at <www.whocc.no/atcddd/>. A free,
searchable database of ATC/DDD codes is available on this
site, and other excellent resources are for sale, including guide-
lines for ATC classification and DDD assignment.
The European Union has identified the measurement of
antibiotic consumption as a high priority item and has 
established the European Surveillance of Antibiotic
Consumption (ESAC) project. It is a DG SANCO (Health
and Consumer Protection Directorate General)-funded 
monitoring programme, which collects standardized, harmo-
nized and comparable data on antibiotic consumption. The
goal of ESAC is to document variations in antibiotic con-
sumption and translate them into quality indicators for public
health monitoring over time and place in order to target inter-
ventions and to assess the effectiveness of prevention pro-
grammes. Excellent information about the project and
antibiotic measurement in general is available on the ESAC
website at <www.esac.ua.ac.be>. It also serves as a source for
comparative consumption statistics.
An excellent tool for the application of ATC/DDD, the
Antibiotic Consumption Calculator created by Dominique L
Monnet of the Statens Serum Institute in Copenhagen, is
available for free download on the home page of the European
Society of Clinical Microbiology and Infectious Diseases
Study Group on Antibiotic Policies (ESGAP) at
<www.escmid.org/sites/science/studygroups/ index.asp> (click
‘ESGAP’, then ‘News & Activities’).
Dr Ingrid Sketris of Dalhousie University has published a
superb manual entitled ‘A Canadian Guide for Drug
Utilization Studies Using Administrative Claims Data: Focus
on the WHO ATC System and Defined Daily Dose’ (17). It
was developed as part of a Health Transitions Fund Project and
gives excellent practical advice to those interested in popula-
tion drug statistic methodology.
Measurement of antibiotic consumption: ATC/DDD methodology
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